You just read:

DelMar Pharmaceuticals and MD Anderson Initiate New Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

News provided by

DelMar Pharmaceuticals, Inc.

Jan 25, 2017, 08:30 ET